Zynerba Pharmaceuticals

Receive alerts
Market Cap:
$273.5 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 33


Zynerba boosts cash position in 2Q, gears up for top-line data from key trials with Zygel CBD gel

The company has a cash pile of $88.7 million to fund operations and reach clinical milestones in the first half of 2020...

2 weeks, 1 day ago

Zynerba Pharmaceuticals joins Russell 3000 and Russell 2000 indexes

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies...

on 07/01/2019

Zynerba wins new US patent for treatment of Autism Spectrum Disorder with CBD

The patent comes at an opportune times as enrollment speeds up in Zynerba’s open label Phase 2 BRIGHT study evaluating the safety, and potency of its Zygel CBD gel ...

on 06/11/2019

Zynerba tells FDA it should regulate CBD and cannabis-derived products like standard pharmaceuticals

The FDA is holding its first public hearing on how it should regulate cannabis and CBD, and the agency asked Zynerba and others involved with the plant to comment ...

on 05/31/2019

Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition

The disorder is caused by a small missing piece of the 22nd chromosome that can affect every system in the body...

on 05/29/2019

Zynerba boosts cash position in 1Q, gears up for top-line data from four key trials with Zygel CBD gel

The company has a cash pile of $68.3 million to fund operations and reach clinical milestones in the first half of 2020...

on 05/08/2019

Zynerba Pharmaceuticals scores Fast Track FDA designation for Zygel CBD gel

US regulators have awarded the distinction to expedite the development of the drug to treat Fragile X syndrome...

on 05/06/2019

Zynerba rockets as investors await CEO's presentation at London conference

The 2019 HC Wainwright Global Life Sciences Conference will take place on April 9 at the Grosvenor House...

on 04/03/2019

Zynerba’s 4Q shows momentum as it heads into key clinical trial

CEO Armando Anido says the company’s strong cash position is expected to take it through its NDA submission and potential approval for Zygel in Fragile X syndrome...

on 03/11/2019

Zynerba Pharmaceuticals launches Phase 2 trial of Zygel in autism spectrum disorder

The Pennsylvania-based company which is doing trail-blazing work pushing clinical trials for cannabis-derived treatments, expects to present top-line data from the study in the first half of 2020...

on 03/07/2019

Zynerba Pharmaceuticals receives new US patent for treatment of Fragile X syndrome with CBD

The new patent which expires in 2038, is part of an expanding intellectual property portfolio covering Zynerba’s flagship ZYN002 synthetic CBD gel...

on 02/26/2019

Zynerba Pharmaceuticals’ quest for CBD gel to treat Fragile X syndrome ventures where big pharma fears to tread

With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals ...

on 02/22/2019

Zynerba Pharmaceuticals adds pharma exec to its board

Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies ...

on 02/20/2019

Proactive Investors cannabis conference in New York showcases industry potential for investors

More than 100 attendees heard updates from Alchemist, ICOX Innovations, Pharmalogyx, Pressure BioSciences and Zynerba Pharmaceuticals...

on 01/31/2019

Proactive Investors conference in New York focuses on small-cap cannabis industry

Participating companies are Alchemist Inc, ICOX Innovations, Pharmalogyx, Pressure BioSciences and Zynerba Pharmaceuticals ...

on 01/30/2019

Zynerba Pharmaceuticals stock soars amid slew of positive drivers

Mad Money host Jim Cramer said he expects 'marijuana-adjacent' biotechnology companies to start getting more credit from investors for their cannabis-influenced businesses...

on 01/30/2019

SCYNEXIS names Zynerba CEO Armando Anido to its board

Anido boasts more than 30 years of experience in the biopharmaceutical sector...

on 01/22/2019

Zynerba on track to report cannabidiol gel treatment results for Fragile X childhood disorder

The company has completed enrollment for its Phase 2 clinical trial of the gel's use with children and adolescents with developmental and epileptic encephalopathy...

on 12/19/2018

Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products

The treatment Zynberba is developing is for Fragile X Syndrome, the leading known genetic cause of both inherited intellectual disability and autism spectrum disorder...

on 11/05/2018

Are marijuana stocks too high for an investor tempted to join the party, or do they have room to run?

Cronos stock recovers on Friday after saner voices intervened and defended the Canadian cannabis stock from a classic short-selling attack...

on 09/03/2018

Small-Cap Snapshot: SAExploration receives court approval to purchase Geokinetics’ assets

The assets listed in the agreement include machinery, seismic processing software and other equipment ...

on 07/20/2018